Filing Details
- Accession Number:
- 0001127602-18-009804
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-05 08:19:17
- Reporting Period:
- 2018-03-01
- Accepted Time:
- 2018-03-05 08:19:17
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1472091 | Edge Therapeutics Inc. | EDGE | Pharmaceutical Preparations (2834) | 264231384 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1652973 | A Brian Leuthner | 300 Connell Drive, Suite 4000 Berkeley Heights NJ 07922 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-03-01 | 2,500 | $14.81 | 72,736 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-03-02 | 2,500 | $15.08 | 70,236 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right To Purchase) | Acquisiton | 2018-03-01 | 280,000 | $0.00 | 280,000 | $14.98 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 280,000 | 2028-03-01 | No | 4 | A | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 162,000 | Indirect | By Spouse |
| Common Stock | 223,622 | Indirect | By Trust |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $14.44 to $15.29 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $14.79 to $15.31 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- This option, representing a right to purchase a total of 280,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.
Billionaire Hedge Funds
